Pfizer Corporation

Wyeth

Bounthon Loun

Lakshmi Khandke

Rasappa Gounder Arumugham

Kathrin Ute Jansen

Annaliesa Sybil Anderson

Gary Warren Zlotnick

Leah Diane Fletcher

Thomas Richard Jones

John Erwin Farley

John Lance Perez

Shannon Lea Harris

Rasappa Arumugham

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 &#x3bc;g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 &#x3bc;g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

compositions and methods thereof

[object Object]

The present invention relates to stable formulations ofrLP2086 Subfamily B Antigens in immunogenic compositions. The present invention also relates to methods of preserving the conformation ofrLP2086 Antigens and methods for determining the potency ofrLP2086 antigens.

Growing community of inventors

North Reading, MA, United States of America

Bounthon Loun